Molecular structure of R-848, CAS Number: 144875-48-9
R-848 (CAS 144875-48-9)
See product citations (12)
Alternate Names:
Resiquimod; S 28463
Application:
R-848 is an immune response modifier and TLR7 and TLR8 activator
CAS Number:
144875-48-9
Purity:
≥98%
Molecular Weight:
314.39
Molecular Formula:
C17H22N4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
R-848, also known as Resiquimod, is a synthetic compound that plays a pivotal role in immunological research due to its unique mechanism of action as an immune response modifier. It specifically targets and binds to toll-like receptors (TLRs) 7 and 8, which are components of the innate immune system. Upon binding, R-848 initiates a complex signaling cascade that culminates in the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). This transcription factor is instrumental in the upregulation of pro-inflammatory cytokines, type I interferons, and other mediators that are essential for the innate immune response. The ability of R-848 to modulate TLR signaling makes it an invaluable tool for researchers aiming to elucidate the pathways underlying innate immunity and the inflammatory response. Additionally, its role in stimulating a robust immune response without the direct involvement of pathogens provides a unique model for studying the effects of immune modulation in various experimental applications.
R-848 (CAS 144875-48-9) References
- Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. | Ahonen, CL., et al. 1999. Cell Immunol. 197: 62-72. PMID: 10555997
- The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. | Burns, RP., et al. 2000. Clin Immunol. 94: 13-23. PMID: 10607486
- The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. | Tomai, MA., et al. 2000. Cell Immunol. 203: 55-65. PMID: 10915562
- Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. | Bishop, GA., et al. 2000. J Immunol. 165: 5552-7. PMID: 11067909
- The immune response modifier resiquimod mimics CD40-induced B cell activation. | Bishop, GA., et al. 2001. Cell Immunol. 208: 9-17. PMID: 11277614
- Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. | Hemmi, H., et al. 2002. Nat Immunol. 3: 196-200. PMID: 11812998
- The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. | Brugnolo, F., et al. 2003. J Allergy Clin Immunol. 111: 380-8. PMID: 12589360
- Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. | Wu, JJ., et al. 2004. Antiviral Res. 64: 79-83. PMID: 15498602
- Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. | Caron, G., et al. 2005. J Immunol. 175: 1551-7. PMID: 16034093
- The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. | Hattermann, K., et al. 2007. FASEB J. 21: 1575-85. PMID: 17264163
- TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes. | Shen, E., et al. 2008. Scand J Immunol. 67: 560-8. PMID: 18397197
- Exhaustive exercise reduces TNF-α and IFN-α production in response to R-848 via toll-like receptor 7 in mice. | Yano, H., et al. 2010. Eur J Appl Physiol. 110: 797-803. PMID: 20602110
- R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes. | Nian, H., et al. 2012. BMC Infect Dis. 12: 5. PMID: 22243920
- In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. | Theile, D., et al. 2021. Eur J Pharm Sci. 162: 105826. PMID: 33813039
- Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. | Wagner, TL., et al. 1999. Cell Immunol. 191: 10-9. PMID: 9918682
Inhibitor of:
C20orf79, Siglec-H, TLR7, TLR9, and toll.Activator of:
α-defensin 6, β-defensin 111, 2010002M12Rik, Azi2, B lymphocytes, BPIL2, BPIL3, CD14, CD16-2, CD1A, CD209b, CD209e, CD3, CLEC-1, CLEC-5A, CLEC-9A, CS1, DC Marker, DC-SIGN, DDX60L, DEC-205, Dendritic Cell marker, Diphtheria Toxoid, EG432555, Follicular DC Marker, Francisella tularensis LPS, GBP4, GBP7, Gight chain, H2-M1, H60a, Hep C cAg, HLA-DR, HNP-3, IFI-16, IFI-203, IFI-205, IFI-35, IFIT1, IFIT1L, IFIT2, IFIT3, IFITM7, IFN-α1, IFN-α10, IFN-α11, IFN-α13, IFN-α14, IFN-α16, IFN-α2, IFN-α5, IFN-α6, IFN-α8, IFN-αB, IFN-β, IFN-γ, IFN-ω, Ig κ, IgA2, IgG κ light chain, IgG Fab fragment, IgG2a, IgG2c, Igk-C, IL-1α, IL-11Rα1, IL-12A p35, IL-12B p40, IL-12B p70, IL-17REL, IL-18R, IL-1RI, IL-23, IL-26, IL-28, IL-28R, IL-TIFb, ILT-6, ILT-7, IRF-2BP2, IRF-5, ISG12a, ISG12b2, ISG15, ISG43, Limitin, LST1, LYSMD4, MB21D2, MDA5, MEK-7, MHC, MHC class I, MIP-1β, MIP-2, Mx3, MxB, MyD88, NAIP1, NOD3, Oas1b, Oas1c, Oas1d, Oas1g, OASL, OASL1, Optineurin, OTTMUSG00000007655, OTTMUSG00000011262, OTTMUSG00000011269, OTTMUSG00000011275, PGRP-Iα, Plasmacytoid DC Marker, Properdin, Rheumatoid Factor, RP105, RT1-A, Salmonella O, SARM, SIRP-β1b, Spi-B, Stat2, TALL-1, TAP, TICAM-1, TICAM-2, TIM-4, TLR1, TLR10, TLR12, TLR13, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TMEM143, TRAF1, TREM-1, TRIM56, UNC93B1, and Yersinia pestis F1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
R-848, 5 mg | sc-203231 | 5 mg | $102.00 | |||
R-848, 25 mg | sc-203231A | 25 mg | $306.00 | |||
R-848, 100 mg | sc-203231B | 100 mg | $510.00 | |||
R-848, 500 mg | sc-203231C | 500 mg | $1559.00 |